This is a revised application for a Fogarty International Research Collaboration Award (FIRCA). The PI of the application is Dr. Teresita Bellido from the Center of Osteoporosis and Metabolic Bone Diseases of the University of Arkansas for Medical Sciences, USA. The foreign collaborator is Dr. Ricardo Boland from the Department of Biology, Biochemistry and Pharmacy of the Universidad Nacional del Sur, Argentina. The work proposed is an extension of an NIH-funded """"""""parent grant"""""""" lead by the PI (see under Performance Site) and will be primarily performed in Argentina taking advantage of the expertise of the foreign collaborator. Studies by Dr. Bellido's laboratory demonstrated that bisphosphonates (BPs) prevent osteocyte and osteoblast apoptosis in vitro and in vivo, by a novel mechanism that involves the opening of hemichannels containing connexin43 (Cx43) (but not other connexins), with the subsequent activation of Src kinases, followed by activation of the extracellular signal regulated kinases (ERKs). Studies from Dr. Boland's laboratory demonstrated the presence of specific binding sites for the BP olpadronate in ROS17/2.8 rat osteosarcoma derived cells. ERKs can be activated by a variety of stimuli through the engagement of appropriate receptors, however receptors for BPs have not been described. Based on the lines of evidence from both laboratories, the PI proposes the hypothesis that opening of Cx43 hemichannels and subsequent activation of intracellular signaling is initiated by binding of bisphosphonates to extracellular domains of Cx43. To test this hypothesis, the PI and her collaborator propose the following specific aims to be completed in a three-year funding period.
Specific Aim 1 : Characterize the binding properties of the BP alendronate to Cx43-expressing cells, by determining the affinity constant (Kd), number of binding sites (Nmax), and binding specificity by competition analysis.
Specific Aim 2 : Map the domains of Cx43 involved in the BP binding by blocking specific regions of Cx43 using specific antibodies and blocking peptides.
Specific Aim 3 : Examine whether, similar to the anti-apoptotic actions of BPs mediated by ERKs, BPs activate other intracellular signaling cascades through Cx43 hemichannels that are responsible for the proliferative and differentiating effects of these agents on cells of the osteoblastic lineage. Funding of this FIRCA will allow the PI to answer an important scientific question in a timely manner, will foster research of high scientific merit beneficial for both the PI and her foreign collaborator, and will enhance the research capabilities at the foreign site.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Small Research Grants (R03)
Project #
5R03TW006919-02
Application #
7119614
Study Section
International and Cooperative Projects 1 Study Section (ICP)
Program Officer
Katz, Flora N
Project Start
2005-09-01
Project End
2008-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$31,851
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Lezcano, V; Bellido, T; Plotkin, L I et al. (2014) Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res 324:30-9
Bellido, Teresita (2014) Osteocyte-driven bone remodeling. Calcif Tissue Int 94:25-34
Plotkin, Lilian I; Bellido, Teresita (2013) Beyond gap junctions: Connexin43 and bone cell signaling. Bone 52:157-66
Bivi, Nicoletta; Condon, Keith W; Allen, Matthew R et al. (2012) Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 27:374-89
Lezcano, V; Bellido, T; Plotkin, L I et al. (2012) Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys 518:95-102
Bivi, Nicoletta; Lezcano, Virginia; Romanello, Milena et al. (2011) Connexin43 interacts with ?arrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone. J Cell Biochem 112:2920-30
Rhee, Yumie; Allen, Matthew R; Condon, Keith et al. (2011) PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res 26:1035-46
Bellido, Teresita; Plotkin, Lilian I (2011) Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49:50-5
Rhee, Yumie; Bivi, Nicoletta; Farrow, Emily et al. (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49:636-43
Plotkin, L I; Bivi, Nicoletta; Bellido, T (2011) A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49:122-7

Showing the most recent 10 out of 11 publications